Financial Performance - Total operating revenue for the year reached RMB 6,895,625,987.71, a 42% increase compared to RMB 4,856,325,303.14 in the same period last year[10]. - Net profit for the year was RMB 357,063,981.07, up 75% from RMB 203,580,510.36 year-on-year[11]. - Operating profit for the year was RMB 336,807,352.78, compared to RMB 154,370,418.62 in the same period last year, marking a 118% increase[10]. - The company reported a total comprehensive income of RMB 356,248,878.85, significantly higher than RMB 174,477,777.84 from the previous year[11]. Assets and Liabilities - The company reported a total asset of RMB 124.90 billion as of March 31, 2025, an increase from RMB 122.47 billion at the beginning of the year, representing a growth of approximately 1.96%[8]. - The total liabilities amounted to RMB 76.37 billion, up from RMB 74.31 billion, indicating a rise of about 2.78%[7]. - The company's cash and cash equivalents decreased to RMB 10.07 billion from RMB 12.44 billion, reflecting a decline of approximately 19.06%[7]. - The cash and cash equivalents at the end of the period were RMB 6,622,362,052.90, down from RMB 8,250,603,050.59 at the end of the previous year[16]. - Total assets paid in cash amounted to RMB 4,581,750,052.63, compared to RMB 3,804,067,677.22 in the previous year[14]. Equity and Retained Earnings - The company's equity attributable to shareholders rose to RMB 35.53 billion from RMB 35.29 billion, marking an increase of approximately 0.68%[8]. - The company's cash flow from operating activities generated a net amount of RMB 608,315,989.61, recovering from a negative cash flow of RMB -201,046,083.32 in the previous year[13]. - The company reported a net profit margin improvement, with retained earnings increasing to RMB 1.59 billion from RMB 1.36 billion, a growth of about 17.43%[8]. Investment and Development - The company has allocated RMB 470.49 million for development expenditures, up from RMB 423.82 million, indicating an increase of approximately 11.00%[8]. - Research and development expenses increased to RMB 367,893,190.02, representing a 46% rise from RMB 252,485,316.73 in the previous year[10]. - The company recorded an increase in investment income to RMB 8,538,734.77, compared to RMB 1,946,087.22 in the same period last year[10]. Financing Activities - The company issued green technology innovation bonds with a registered amount of RMB 5 billion, valid for two years, to support its financing activities[3]. - Cash flow from financing activities showed a net increase of RMB 2,115,512,363.21, down from RMB 4,720,994,941.62 in the same period last year[16]. Strategic Plans - The company plans to expand its market presence and invest in new technologies to enhance its competitive edge in the industry[4]. - The company aims to strengthen its financial position through strategic debt management and capital allocation[4].

Financial Performance - In Q1 2025, the company's sales revenue was $2,247.2 million, representing a 1.8% increase from Q4 2024's $2,207.3 million and a 28.4% increase from Q1 2024's $1,750.2 million[5]. - The gross profit for Q1 2025 was $505.9 million, compared to $499.0 million in Q4 2024, marking a 1.4% increase, and a significant 111.0% increase from Q1 2024's $239.7 million[5]. - The gross margin for Q1 2025 was 22.5%, slightly down from 22.6% in Q4 2024, and significantly up from 13.7% in Q1 2024[5]. - Net profit for Q1 2025 was $323.4 million, a 19.4% increase from $270.9 million in Q4 2024, and a 409.2% increase from $63.5 million in Q1 2024[16]. - The company reported a basic and diluted earnings per share of $0.02 for Q1 2025, compared to $0.01 in Q4 2024 and Q1 2024[16]. - Operating profit for Q1 2025 increased to $309,571, up from $214,467 in Q4 2024, marking a growth of 44.3%[31]. - The company reported a net profit of $323,422 for Q1 2025, compared to $270,946 in Q4 2024, an increase of 19.4%[31]. Operating Expenses - Operating expenses in Q1 2025 were $196.3 million, a decrease of 31.0% from $284.5 million in Q4 2024, and a decrease of 17.3% from $237.3 million in Q1 2024[5]. - Research and development expenses for Q1 2025 were $148,899, down 31.3% from $217,035 in Q4 2024[31]. Capacity and Production - Capacity utilization increased to 89.6% in Q1 2025, up by 4.1 percentage points from the previous quarter[7]. - Total wafer sales reached 2,292,153 units in Q1 2025, representing a 15.1% increase from 1,991,761 units in Q4 2024 and a 27.7% increase from 1,794,891 units in Q1 2024[19]. - The capacity utilization rate improved to 89.6% in Q1 2025 from 85.5% in Q4 2024[19]. Cash Flow and Assets - Cash and cash equivalents decreased to $4,587,349 thousand in Q1 2025 from $6,364,189 thousand in Q4 2024[27]. - Net cash used in operating activities for Q1 2025 was $(160,415), a significant decrease from $1,449,842 in Q4 2024[37]. - Total assets as of March 31, 2025, were $47,965,391, down from $49,161,248 at the end of 2024[35]. Liabilities and Equity - Total liabilities decreased to $15,738,909 as of March 31, 2025, from $17,291,590 at the end of 2024[35]. - The company’s total equity increased to $32,226,482 from $31,869,658, reflecting a growth of 1.1%[35]. - The debt-to-equity ratio was 34.9% in Q1 2025, down from 36.4% in Q4 2024[27]. Future Outlook - The company expects Q2 2025 revenue to decline by 4% to 6%, with a gross margin guidance of 18% to 20%[8]. - The company aims to enhance its resilience and risk management capabilities while focusing on its core business in the second half of 2025[8]. Regional Performance - Revenue from the China region accounted for 84.3% in Q1 2025, a decrease from 89.1% in Q4 2024 and an increase from 81.6% in Q1 2024[17]. Other Income - Other income, net for Q1 2025 was $39.7 million, a significant decrease of 71.8% from $140.8 million in Q4 2024[16]. Capital Expenditures - Capital expenditures for Q1 2025 were $1,415.5 million, down from $1,660.1 million in Q4 2024[20].

Financial Performance - For Q1 2025, Autohome reported total net revenue of RMB 1,453.8 million (USD 200.3 million), a decrease from RMB 1,609.1 million in Q1 2024, representing a year-over-year decline of approximately 9.6%[9]. - The net profit attributable to Autohome for Q1 2025 was RMB 356.6 million (USD 49.1 million), down from RMB 394.5 million in Q1 2024, reflecting a decrease of about 9.6%[18]. - Autohome's media services revenue for Q1 2025 was RMB 242.2 million (USD 33.4 million), down from RMB 327.4 million in Q1 2024, primarily due to reduced advertising spending from fuel vehicle manufacturers[15]. - The adjusted net profit for Q1 2025, according to non-GAAP measures, was RMB 420.8 million (USD 58.0 million), compared to RMB 493.9 million in Q1 2024[9]. - In Q1 2025, Autohome's adjusted net profit attributable to the company was RMB 420.8 million (USD 58.0 million), a decrease from RMB 493.9 million in Q1 2024, representing a decline of approximately 14.8%[20]. - The basic and diluted earnings per share for Q1 2025 were RMB 0.72 (USD 0.10) and RMB 0.71 (USD 0.10), respectively, compared to RMB 0.78 in the same period of 2024[19]. - The adjusted basic and diluted earnings per share for Q1 2025 were RMB 0.88 (USD 0.12), down from RMB 1.02 in the same period of 2024, indicating a decrease of about 13.7%[20]. - The net profit margin for the three months ended March 31, 2024, was 24.5%[32]. - The company reported a net profit attributable to shareholders of RMB 379,776 for the three months ended March 31, 2024, compared to RMB 340,450 in 2025, marking an increase of 11.6%[31]. User Engagement and Product Development - Daily active users on mobile reached 76.92 million in March 2025, marking a year-over-year increase of 10.8%, driven by category expansion and continued investment in quality content[8]. - The company launched an upgraded version of the Autohome App at the end of March 2025, featuring an AI assistant developed using DeepSeek and proprietary big data resources, enhancing user decision-making efficiency[8]. Operational Metrics - Research and development expenses for Q1 2025 totaled RMB 274.1 million (USD 37.8 million), a decrease from RMB 336.1 million in Q1 2024, mainly due to lower personnel-related costs[16]. - The total number of employees as of March 31, 2025, was 4,345, including 1,299 employees from Tian Tian Pai Che[22]. - The net cash flow from operating activities for Q1 2025 was RMB 134.7 million (USD 18.6 million)[21]. - As of March 31, 2025, the company's cash and cash equivalents, along with short-term investments, totaled RMB 21.93 billion (USD 3.02 billion)[21]. Corporate Actions and Future Outlook - The company repurchased 4,781,999 American Depositary Shares for approximately USD 128.0 million as of May 2, 2025[9]. - Autohome's new retail business has expanded to nearly 200 locations, providing partners with leading technology capabilities and quality offline resources[8]. - Autohome will hold its earnings conference call on May 8, 2025, at 8:00 AM ET (8:00 PM Beijing time)[23]. - The company emphasizes the importance of adjusted non-GAAP financial metrics to assess operational performance, which excludes non-cash expenses and non-operating gains/losses[27][28]. - Autohome's mission is to leverage technology to continuously reduce decision-making and transaction costs in the automotive industry[26]. - The company provides a wide range of services including automotive finance, insurance, used car transactions, and after-sales services through its website and mobile applications[26]. Financial Position - Total assets as of March 31, 2025, were RMB 29,011,574, a decrease from RMB 30,221,625 as of December 31, 2024[34]. - Cash and cash equivalents increased to RMB 2,157,997 as of March 31, 2025, from RMB 1,693,597 as of December 31, 2024[34]. - The total liabilities decreased to RMB 3,756,967 as of March 31, 2025, from RMB 5,020,975 as of December 31, 2024[34].

Revenue and Profitability - Revenue for the period reached 540,937 million, representing a 17.6% increase compared to the previous period[9] - The company reported a net profit of 49,997 million, with a profit margin of 9.2%[9] - The gross margin improved to 68.7%, up from 61.4% in the previous period[9] - The company reported a total revenue of $5,967,555 for the latest quarter, showing an increase from $5,859,117 in the previous quarter[37] - The net income for the quarter was $(55,407), compared to $(45,118) in the prior quarter, indicating a decline in profitability[39] - The company achieved a gross margin of 29.12%, slightly down from 31.46% in the previous quarter[37] Capital Expenditures and Investments - Capital expenditures for the period were 12,286,786 million, reflecting a 27.7% increase year-over-year[30] - Research and development expenses increased to $1,441,057, reflecting a commitment to innovation and new technology[37] - The company plans to pursue strategic acquisitions to enhance its product offerings, with a budget of $500 million allocated for potential deals[37] Market Performance and Share - The company achieved a market share of 81.8% in the MOSFET segment, with sales of 442,458 million[14] - The 65nm technology segment generated 124,280 million, accounting for 23.0% of total revenue[20] - The company is focusing on market expansion in Asia, targeting a 15% increase in market share by the end of the year[37] Future Guidance and Projections - Future guidance indicates expected revenue growth of 10% for the next quarter[9] - Future guidance indicates expected revenue growth of approximately 10% for the next quarter, projecting revenues around $6.57 billion[37] - New product launches are anticipated to contribute an additional $200 million in revenue over the next fiscal year[37] Operational Efficiency - The overall operating expenses decreased by 12.2% compared to the previous period[29] Strategic Initiatives - The company is exploring potential mergers and acquisitions to enhance market presence and technological capabilities[9] - The company plans to expand its product line with new technologies in the MCU and IGBT sectors[19] User Engagement - User data showed a significant increase in active users, reaching 6,771,034, up from 6,582,605 in the previous quarter[37] Financial Health - The total liabilities decreased to $4,459,132, down from $5,585,181, indicating improved financial health[39]

Business Performance - The new business value in the insurance sector reached a record high, with a year-on-year growth of 43% in Asia, contributing to a 36% increase in new business value overall [4]. - Core earnings for Q1 2025 were CAD 1.767 billion, a decrease of 1% compared to Q1 2024, while net income attributable to shareholders was CAD 485 million, down 47% [6]. - Core EPS increased by 3% to CAD 0.99, while overall EPS fell by 48% to CAD 0.25 [6]. - APE sales rose by 37% to CAD 2.689 billion, and new business CSM increased by 31% to CAD 907 million [6]. - In Q1 2025, core earnings were CAD 1.8 billion, a decrease of 1% compared to Q1 2024 [13]. - Net income attributable to shareholders in Q1 2025 was CAD 500 million, down CAD 400 million from Q1 2024, primarily due to increased net provisions from market experience [14]. - APE sales, new business CSM, and new business value in the insurance sector grew by 37%, 31%, and 36% year-over-year, respectively, in Q1 2025 [15]. - Core earnings for Q1 2025 totaled CAD 1,767 million, a decrease from CAD 1,907 million in Q4 2024 but an increase from CAD 1,710 million in Q1 2024 [24]. - The net income attributable to shareholders for Q1 2025 was CAD 485 million, down from CAD 1,638 million in Q4 2024 and CAD 866 million in Q1 2024 [24]. Financial Metrics - The LICAT ratio remained strong at 137%, and the financial leverage ratio was 23.9%, within the mid-term target range of 25% [4]. - The core EBITDA margin for the global wealth and asset management business expanded by 290 basis points to 28.4% [8]. - The market experience loss for Q1 2025 was CAD 1,332 million, compared to a loss of CAD 192 million in Q4 2024 and a loss of CAD 779 million in Q1 2024 [24]. - The company reported a core earnings tax adjustment of $331 million for Q1 2025, consistent with the effective rates applied during the reporting period [31]. - The company reported a total investment income of $3,242 million for Q1 2025, down from $4,628 million in Q4 2024 [49]. - The company’s total income before tax was $1,252 million, with a significant contribution from the Asia segment at $594 million [35]. - The company’s core earnings tax adjustment for Q1 2024 was $330 million, reflecting the effective tax rate applied [37]. Market and Strategic Initiatives - The company launched FutureStepTM, a new digital retirement plan product for small businesses in the U.S., enhancing its market presence [9]. - A strategic partnership with China Banking Corporation was extended for 15 years to provide comprehensive financial solutions in the Philippines [9]. - The company completed a reinsurance transaction with Reinsurance Group of America, releasing capital to be returned to shareholders through a new share buyback plan [9]. - The company is focusing on expanding its market presence and enhancing its product offerings as part of its strategic initiatives [23]. - The company plans to return capital through share buybacks as part of its strategy to achieve mid-term financial and operational goals [50]. Regional Performance - In Asia, APE sales, new business CSM, and new business value reached record highs, growing by 50%, 38%, and 43% year-over-year, respectively [18]. - In Canada, APE sales increased by 9%, with new business value growing by 15% compared to Q1 2024 [18]. - The net income from Asia for Q1 2025 was $624 million, up from $583 million in Q4 2024, while the U.S. reported a loss of $569 million [45]. - The net income from Canada for Q1 2025 was $222 million, a decrease from $439 million in Q4 2024 [45]. Risks and Uncertainties - The company emphasizes that forward-looking statements are subject to significant risks and uncertainties, which may cause actual results to differ materially from expectations [50]. - Key factors affecting actual performance include general business and economic conditions, market volatility, interest rates, and credit spreads [52]. - Future performance may be influenced by geopolitical uncertainties, including international disputes and trade issues [52]. - The potential impact of climate change and environmental factors on the company's operations is acknowledged as a significant risk [52]. - The company acknowledges the importance of adapting to market changes and retaining key personnel to ensure operational effectiveness [52].

Sales Performance - Total sales volume for Q1 2025 was 19,741 million liters, a decrease of 6.1% compared to Q1 2024[13] - In Q1 2025, sales volume in China decreased by 9.2%, with inventory management measures accounting for approximately 25% of the decline[16] - Total sales volume for Q1 2025 decreased by 6.1% to 19,741 thousand liters compared to Q1 2024[39] - In the Asia-Pacific region, sales volume in the eastern region increased by 11.9% year-over-year, while the western region saw a decline of 8.6%[43] Revenue and Profitability - Revenue for Q1 2025 was $1,461 million, down 7.5% from $1,643 million in Q1 2024[8] - Revenue in China fell by 12.7%, while revenue per hundred liters decreased by 3.9%[16] - Total revenue for Q1 2025 was $1,461 million, compared to $1,643 million in Q1 2024, reflecting a decline of 11.1%[42] - Normalized net profit attributable to equity holders was $235 million, down from $297 million in Q1 2024[10] - The net profit for Q1 2025 was $242 million, down from $293 million in Q1 2024, representing a decrease of 17.4%[42] EBITDA and Operating Profit - Normalized EBITDA for Q1 2025 was $485 million, reflecting an 11.2% decrease from $572 million in Q1 2024[9] - Normalized EBITDA decreased by 17.1% due to revenue performance and operational deleveraging[16] - Normalized EBITDA for Q1 2025 dropped by 14.4% to $331 million, down from $408 million in Q1 2024[39] - The normalized operating profit (EBIT) for Q1 2025 was $331 million, compared to $408 million in Q1 2024, a decline of 18.9%[42] Cost and Margin Analysis - Cost of sales for Q1 2025 was $716 million, a reduction of 7.5% compared to the previous year[6] - The gross profit margin for Q1 2025 was 51.0%, slightly down from 51.5% in Q1 2024[13] - The normalized EBITDA margin for Q1 2025 was 33.2%, down 140 basis points from 34.8% in Q1 2024[39] - The company reported a normalized operating margin of 33.2% for Q1 2025, down from 34.8% in Q1 2024[42] Market Challenges and Strategies - The company faced challenges in the Chinese market due to unfavorable regional and channel mix, impacting sales performance[12] - The company remains focused on its brand portfolio, marketing channels, and agile team to navigate the current market environment[5] - The company launched a new packaging design for Budweiser in March 2025 to attract a new generation of adult consumers[16] - In Q1 2025, the sales of zero-sugar Harbin Ice Pure increased by approximately 70%, connecting with health-conscious young adults[16] - The company’s marketing resources were increased for Budweiser and Harbin to strengthen brand power and market share[16] Financial Overview - The financial data presented is normalized to exclude the effects of currency conversion and scope changes related to acquisitions and divestitures[38] - The financial performance metrics are based on internal records and are not independently audited[38] - The effective tax expense for Q1 2025 was $95 million, compared to $117 million in Q1 2024, indicating a reduction in tax burden[42] Company Background - The company operates in two geographical segments: Eastern Asia Pacific (mainly Korea, Japan, and New Zealand) and Western Asia Pacific (China, India, Southeast Asia, and exports)[41] - The company employs over 21,000 staff across 47 breweries in the Asia Pacific region[36] - The company is a subsidiary of Anheuser-Busch InBev, which has over 600 years of brewing history[36]

Financial Performance - Revenue for the six months ended March 31, 2025, was HKD 266,472,000, a decrease of 23.1% compared to HKD 346,304,000 for the same period in 2024[3] - Gross profit for the same period was HKD 28,994,000, down 14.4% from HKD 33,860,000 in 2024[3] - Profit before tax decreased to HKD 7,873,000, a decline of 45.5% from HKD 14,468,000 in the previous year[3] - Net profit for the period was HKD 6,169,000, down 34.5% compared to HKD 9,384,000 in 2024[3] - The company's revenue for the six months ended March 31, 2025, was approximately HKD 266.5 million, a decrease of HKD 79.8 million or 23.1% compared to the same period in 2024[35] - The cost of sales during the same period was approximately HKD 237.5 million, down HKD 74.8 million or 23.9% year-over-year, consistent with the revenue decline[35] - The gross profit decreased by approximately HKD 4.9 million, with a gross profit margin rising to about 10.9% compared to 9.8% in 2024[35] - Total employee costs for the six months ended March 31, 2025, were HKD 157,535,000, a decrease of 8.0% from HKD 171,258,000 in the previous year[22] - The net loss from other income and losses decreased by approximately HKD 2.4 million or 98% compared to 2024, mainly due to reduced net losses from fair value changes of financial assets[37] - Financing costs increased by approximately HKD 32,000 or 24.8% compared to 2024, attributed to a new warehouse lease[38] - The total profit and comprehensive income increased by approximately HKD 3.2 million or 34.3% compared to 2024, driven by the net effects of gross profit decline, reduced net losses from financial assets, and increased administrative expenses[39] Earnings and Dividends - Basic and diluted earnings per share were both HKD 0.009, an increase from HKD 0.006 in the previous year[4] - The company declared an interim dividend of HKD 20,004,000, compared to no dividend in the same period last year[4] - The company reported a total of HKD 20,004,030 in interim dividends for the six months ended March 31, 2025, with a declared dividend of HKD 0.03 per share[26][27] Assets and Liabilities - Total assets less current liabilities amounted to HKD 281,166,000, an increase from HKD 275,499,000 as of September 30, 2024[6] - Non-current assets decreased to HKD 7,497,000 from HKD 8,685,000 in the previous period[5] - Current assets included cash and cash equivalents of HKD 150,585,000, up from HKD 123,905,000 as of September 30, 2024[5] - Trade receivables as of March 31, 2025, amounted to HKD 35,758,000, a significant decrease of 67.6% from HKD 110,313,000 as of September 30, 2024[28] - The bank and cash balance was approximately HKD 150.6 million, an increase from HKD 135.9 million as of September 30, 2024[40] Corporate Governance - The board emphasizes accountability and transparency to shareholders, adhering to the corporate governance code as per the listing rules[52] - The audit committee reviews the accounting principles and practices adopted by the group, ensuring compliance with financial reporting matters[54] - The interim performance of the group has not been audited but has been reviewed by the audit committee[55] - The board is not aware of any significant events that require disclosure after the reporting period[57] Business Operations and Future Plans - The company operates primarily in providing electrical engineering services in Hong Kong[8] - The company plans to continue bidding for government projects, which are less affected by external market fluctuations, amid ongoing global economic instability[50] - The company is considering investing in electrical engineering projects to expand its business scope and enhance profitability, currently in the preliminary stage with no agreements signed yet[51] Share Capital - As of March 31, 2025, the company had a total issued share capital of 666,801,000 shares[40] - The average number of ordinary shares for basic earnings per share calculation was 666,801,000 for the six months ended March 31, 2025[23] Other Information - There were no purchases, sales, or redemptions of the company's listed securities during the period[56] - The interim report will be sent to shareholders and published on the company's website at an appropriate time[58]

Financial Performance - Total revenue for Q1 2025 reached $1.12 billion, a 49% increase from $751.65 million in Q1 2024[8] - Product revenue for Q1 2025 was $1.11 billion, up 48% from $746.92 million in the same period last year[8] - GAAP operating profit for Q1 2025 was $11.1 million, a significant improvement from a loss of $261.35 million in Q1 2024, marking a 104% change[8] - Adjusted operating profit for Q1 2025 was $139.36 million, compared to a loss of $147.34 million in the previous year, representing a 195% increase[8] - The company achieved its first GAAP quarterly profit in Q1 2025, with a GAAP net profit of $1.27 million, compared to a loss of $251.15 million in Q1 2024[8] - The company reported a net profit of $0.00 per share in Q1 2025, an improvement from a loss of $0.19 per share in the same period last year[14] - The net profit for Q1 2025 was $1,270,000, a turnaround from a net loss of $251,150,000 in Q1 2024[32] Sales and Market Performance - Global sales of Brukinsa (Zebutinib) amounted to $792 million, reflecting a 62% year-over-year growth[7] - The U.S. remained the largest market, contributing $563 million in product revenue for Q1 2025, up from $351 million in the same quarter last year[9] - Baiyueze® sales in the U.S. reached $563 million in Q1 2025, a 60% increase year-over-year, primarily due to increased demand in CLL indications[13] - Baiyueze® is now approved in 75 markets globally, with recent expansions in Japan, Europe, and Brazil[17] Expenses and Costs - R&D expenses for Q1 2025 were $481.9 million, a 5% increase from $460.6 million in Q1 2024; adjusted R&D expenses rose 4% to $421.2 million[11] - SG&A expenses in Q1 2025 were $459.3 million, up 7% from $427.4 million in Q1 2024, with SG&A expenses accounting for 41% of product revenue, down from 57% year-over-year[12] - Operating expenses totaled $941,175,000 in Q1 2025, compared to $888,065,000 in Q1 2024, marking an increase of approximately 6%[32] Cash Flow and Assets - Cash and cash equivalents as of March 31, 2025, were $2,530,591,000, a slight decrease from $2,638,747,000 as of December 31, 2024[33] - Total assets amounted to $5,841,526,000 as of March 31, 2025, down from $5,920,910,000 at the end of 2024[33] - Net cash provided by operating activities was $44,082 thousand in Q1 2025, a significant improvement from a net cash used of $308,572 thousand in Q1 2024[34] - Cash used in investing activities was $121,941 thousand in Q1 2025, compared to $209,831 thousand in Q1 2024[34] Future Plans and Developments - The company plans to hold an investor R&D day on June 26, 2025, to discuss advancements in its late-stage hematologic and solid tumor pipeline[7] - The company expects to report proof of concept data in various projects related to antibody-drug conjugates, multispecific antibodies, and targeted protein degradation throughout the year[7] - The company expects to complete mid-term analysis for the Phase 3 MANGROVE trial for MCL treatment in the second half of 2025[23] - The company plans to submit a global accelerated approval application for Sotoclar in R/R MCL following data readout from a Phase 2 trial anticipated in late 2025[26] - Baiyueze® tablet formulation is anticipated to receive FDA and EU approval in the second half of 2025[23] Corporate Changes - The company has received shareholder approval to adopt a new English name, BeOne Medicines Ltd., and relocate its registered office to Switzerland[7] - The company has received shareholder approval to change its name to BeOne Medicines Ltd. and relocate its registered office to Switzerland, expected to be completed later this year[26]

Stock Options - The total number of shares available for issuance under the 2023 stock option plan is 38,756,400 shares, accounting for 10.0% of the total issued shares[5] - The number of stock options granted to directors for the year ending March 31, 2024, totals 13,647,000 shares, with an exercise price of HKD 0.574[3] - The total number of stock options granted to employees, excluding the top five highest-paid individuals, is 4,000,000 shares, with an exercise price of HKD 1.12[4] - The total number of stock options for all categories is 34,947,000 shares[4] - The stock options for the top five highest-paid individuals include 3,800,000 shares for one individual who was among the top five in the previous year[8] - The exercise period for the stock options granted spans from the grant date until December 14, 2032[3] - The weighted average closing price of shares prior to the grant date for the stock options was HKD 0.574[8] Company Outlook - The company has not disclosed any new product developments or market expansion strategies in the current announcement[2] - The company has not provided specific future outlook or performance guidance in this announcement[2] - The company maintains that all other information in the 2023/24 annual report remains unchanged[5]

Share Option Scheme - The total number of share options available for grant under the share option scheme as of April 1, 2023, and March 31, 2024, is 100 million shares each [3]. - The total number of shares that can be issued under the share option scheme is 100 million shares, representing 10% of the total issued shares as of the annual report date, excluding treasury shares [3].